For advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations, EGFR‐tyrosine kinase inhibitors (TKIs) have demonstrated higher efficacy than platinum‐based chemotherapy and are now the standard of care for the first‐line therapy [4, 5, 6, 7, 8, 9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.